Navigation Links
Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
Date:10/2/2007

Dana-Farber Campaign is Largest Hospital Fundraising Effort in New England

History

WATERTOWN, Mass., Oct. 2 /PRNewswire/ -- Corey McPherson Nash (CMN), the branding and design studio, is proud to recognize the successful design and development of the case statement supporting Dana-Farber Cancer Institute's capital campaign. CMN developed the case statement, along with additional branding and design work, to support Dana-Farber's efforts to secure the financial resources necessary to accelerate the pace of discovery, speed the application of scientific knowledge, and expand the Institute's ability to provide its signature total patient care.

"Our $1 billion goal marks the most ambitious capital campaign in the Institute's history," said Susan Paresky, Senior Vice President for Development at Dana-Farber Cancer Institute. "We have already seen a tremendous positive response to the campaign."

Dana-Farber Cancer Institute officially launched the campaign, "Mission Possible: The Dana-Farber Campaign to Conquer Cancer," in January 2007. "The success of the capital campaign for Dana-Farber Cancer Institute is extremely important to the Institute and to Corey McPherson Nash," said Michael McPherson, creative director and partner, CMN. "We worked closely with Dana- Farber to ensure that the visual components of this campaign reflect and reinforce the Institute's mission of saving lives. The results of this campaign will ensure that Dana-Farber continues the rigorous research and treatment to make this possible."

For more than 20 years, CMN has helped clients to enhance their communications with thoughtful branding and design. Visit the CMN website at http://www.cmndesign.com.

About Corey McPherson Nash

Corey McPherson Nash, a national branding and design studio, helps organizations achieve measurable brand equity across a wide variety of print and
'/>"/>

SOURCE Corey McPherson Nash
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Bioengineering production strains - Microbia develops new methods
2. Vical Biotech and NIH jointly develops HIV vaccine
3. Kirin Develops a Cure for Bird Flu
4. Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission
5. Georgia Institute of Technology develops doppler Vein finder
6. Hungary Develops New Bird Flu Vaccine
7. Dutch chemical group Akzo Nobel Develops A New Bird Flu Vaccine
8. ICAR develops bird flu vaccine
9. Samsung Develops Device to Measure Body Fat
10. India Develops Test for Diagnosis of Deadly Livestock Disease
11. Mouth Cancer Develops In Two Different Ways
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:General Mills to Cut Sugar in Kids' Cereals 2Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 2Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 4Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 5Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 2Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 3Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 4Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 5
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies 53181 1Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies 53181 2ARDS Promotes Awareness with New Campaign 53177 1ARDS Promotes Awareness with New Campaign 53177 2Immune responses to flu vaccine are diminished in lupus patients 53173 1Immune responses to flu vaccine are diminished in lupus patients 53173 2